PET Imaging of Brain mGluR5 Receptors Using [18F]SP203

Completed · Phase 1

Conditions studied: Healthy, Glutamate Receptor, mGlur5 Protein, Excitatory Amino Acid Receptors, Drug Kinetics, PET Scan

In brief

The metabotropic glutamate subtype five (mGluR5) receptor is a protein found in the brain and is the target for the excitatory chemical messenger glutimate. The purpose of this protocol is to measure mGluR5 receptors in the brain using positron emission tomography (PET) and a research drug called \[18F\]SP203.

Key facts

Study ID

NCT00538798

Run by

National Institute of Mental Health (NIMH)

People needed

50

Starts

2007-09-28

Expected to finish

2015-03-17

Last updated by the study team

2018-07-05

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

• Current psychiatric illness, substance abuse or severe systemic disease based on history and physical exam.
• Laboratory tests with clinically significant abnormalities.
• Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual limits.
• Pregnancy and breast feeding.
• Claustrophobia. (part 1 and 3 only)
• Presence of ferromagnetic metal in the body or heart pacemaker. (part 1 and 3 only)
• Positive HIV test.
• Consumed alcohol within 48 hours before the PET scan.

Where it is running

• National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.